Welcome to our dedicated page for Nutra Pharma SEC filings (Ticker: NPHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Nutra Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Nutra Pharma's regulatory disclosures and financial reporting.
Nutra Pharma Corp. reported a net loss of $459,675 for the three months ended March 31, 2026, narrower than the $1,404,923 loss a year earlier. Net sales were $27,246 and net sales to a related party added $20,968, both down from $73,974 and $36,420 in the prior-year period.
Operating expenses were $398,224, producing a loss from operations of $379,249. A $140,500 gain on settlement of debt partly offset interest and derivative fair-value charges, reducing total other expenses. Cash increased to $21,844 as of March 31, 2026, but operations used $327,791 of cash in the quarter.
The balance sheet remains highly leveraged. Total assets were $616,518 versus total liabilities of $17,878,499, creating a stockholders’ deficit of $17,261,981. The company discloses a working capital deficit of $17,243,345, significant indebtedness in default and extensive convertible notes, many at deep discounts to market.
Management states there is substantial doubt about Nutra Pharma’s ability to continue as a going concern without new financing and improved profitability. As of May 29, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding. The company has also accrued a legal settlement of $680,235 arising from a final judgment in an SEC enforcement action.
Nutra Pharma Corp filed its annual report detailing a biopharmaceutical business focused on venom-derived pain products like Nyloxin and Pet Pain-Away and early-stage drug candidates for autoimmune, viral and neurological diseases. The company reported 2025 revenue of $385,307 and a net loss of $2,047,392, following 2024 revenue of $392,150 and a net loss of $1,285,663. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $78,278,529, a working capital deficit of $16,813,637, and negative operating cash flow. Nutra Pharma highlights Orphan Drug Designation for its RPI‑78M candidate in pediatric multiple sclerosis and outlines plans for future clinical trials and international expansion, all dependent on obtaining adequate financing and higher product sales.
Nutra Pharma Corp. reported modest revenue but continued heavy losses in its quarter ended September 30, 2025. Net sales for the nine months were $228,748, up from $164,436 a year earlier, yet the company posted a nine‑month net loss of $1,558,866.
Nutra Pharma ended the period with cash of only $3,603 and total assets of $709,853, against total liabilities of $17,060,633. Stockholders’ deficit widened to $16,350,780, and management disclosed a working capital deficit of $16,377,977 and substantial doubt about the company’s ability to continue as a going concern.
The company relies heavily on debt and equity funding, including numerous convertible notes, many of which are in default or under negotiation for settlement. As of April 6, 2026, there were 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, reflecting significant leverage and dilution risk.
Nutra Pharma Corp reports Q2 2025 results showing net income of $369,577, reversing a prior-year quarterly loss, largely due to a $704,622 gain from changes in the fair value of convertible notes and derivatives and a $53,526 gain on debt settlements.
Core operations remain weak. For the three months ended June 30, 2025, net sales were $84,532 plus $37,611 to a related party, generating gross profit of only $75,628 against selling, general and administrative expenses of $366,157, resulting in a loss from operations of $290,529. For the six-month period, the company recorded a net loss of $1,035,346.
The balance sheet is highly leveraged, with total assets of $859,068 versus total liabilities of $16,692,328, including $9,345,780 of current debt and $924,516 of derivative liabilities. Stockholders’ deficit was $15,833,260, and the accumulated deficit reached $77,266,483.
Liquidity is strained: cash was only $79,069 at June 30, 2025, after using $693,376 in operating cash during the first half, funded mainly by $810,056 of new convertible notes and officer loans. Management discloses a working capital deficit of $15,888,753, numerous defaulted debts, dependence on external financing, and explicitly states there is substantial doubt about the company’s ability to continue as a going concern, exacerbated by its common stock trading on the OTC Market Group’s Expert Market, which restricts capital-raising options.
Nutra Pharma Corp. reported higher net sales but a much larger loss for the quarter ended March 31, 2025. Net sales rose to $73,974 from $37,732, plus $36,420 of related-party sales, yet the company posted a net loss of $1,404,923 versus $426,934 a year earlier. The deeper loss was driven by operating expenses of $418,150, interest costs, and a $1,007,309 loss from changes in the fair value of convertible notes and derivatives.
Nutra Pharma ended the quarter with only $13,843 of cash, total assets of $775,179, and total liabilities of $16,988,016, resulting in a stockholders’ deficit of $16,212,837. Management discloses substantial doubt about the company’s ability to continue as a going concern, citing an accumulated deficit of $77,636,060, a working capital deficit of $16,296,563, heavy debt—much of it in default, including $9,057,034 of notes—and tight access to capital with its stock on the OTC Expert Market. The company has also accrued $680,235 for an SEC legal judgment and relies on new convertible debt financings to fund operations while it seeks to grow sales of its pain relief products.
Nutra Pharma Corp. filed its annual report detailing 2024 results and continued financial strain. The biopharmaceutical company markets homeopathic pain products like Nyloxin, Pet Pain-Away, Equine Pain-Away and Luxury Feet, and is developing drug candidates RPI-78M and RPI-MN for autoimmune, neurological and viral diseases.
Nutra Pharma reported a 2024 net loss of $1,285,663, following a 2023 net loss of $1,393,356, and disclosed material weaknesses in internal control over financial reporting. Management warns there is substantial doubt about its ability to continue as a going concern without new financing and higher product sales.
The company holds an FDA Orphan Drug Designation for RPI-78M in pediatric multiple sclerosis and aims to start Phase I/II trials in 2026, subject to funding. As of February 17, 2026, Nutra Pharma had 7,159,727,214 common shares and 12,000,000 Series B preferred shares outstanding, and reported non‑affiliate equity market value of $6,762,239 as of its most recent second quarter.
Nutra Pharma Corp. reports another quarterly loss and highlights serious financial strain in its Q3 2024 report. For the nine months ended September 30, 2024, net sales were $164,436 with additional related-party sales of $106,184, while the company recorded a net loss of $1,054,756, similar to the prior year’s loss. Gross profit fell compared with 2023 as operating expenses continued to exceed revenue.
The balance sheet shows total assets of $558,838 against total liabilities of $15,378,402, resulting in a stockholders’ deficit of $14,819,564. The company discloses that it had no cash at period-end, a working capital deficit of $14,902,502, and significant debt, much of it in default or convertible. Management states there is substantial doubt about its ability to continue as a going concern and notes that common stock trades on the OTC Expert Market, which limits capital-raising options.